ArticleCureus2024
Pembrolizumab-Induced Addison's Disease Leading to Severe Hyponatremia in a Breast Cancer Survivor: A Case Report With Implications for Emergency Department Practice.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune checkpoint inhibitor-associated severe hyponatremia: evidence mapping of SIADH-like phenotypes and endocrine immune-related adverse events.Endocrine connections · 2026Article
- Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review.Reviews in endocrine & metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pembrolizumab, a PD-1 inhibitor, has become a cornerstone in the treatment of various cancers, including breast cancer. However, its use is associated with immune-related adverse effects (irAEs), particularly those involving the endocrine system. This case report presents a rare instance of pembrolizumab-induced Addison's disease leading to severe hyponatremia. The case is supported by detailed laboratory findings and evaluated using the Naranjo adverse drug reaction probability scale. A 53-year-old female with a history of breast cancer presented with dizziness and fatigue while on a cruise. Initial laboratory tests revealed severe hyponatremia (serum sodium 117 mEq/L). Further evaluation revealed low cortisol (1.7 µg/dL) and elevated adrenocorticotropic hormone (ACTH) (452 pg/mL), indicative of adrenal insufficiency. Although thyroid function was normal, low IGF-1 levels suggested secondary adrenal insufficiency. The administration of hydrocortisone resulted in rapid symptom improvement, and the patient was discharged with a prescription for ongoing corticosteroid therapy. The Naranjo scale score of 4 indicated a possible relationship between pembrolizumab and the development of Addison's disease. This case underscores the critical need for awareness of irAEs in patients undergoing treatment with immune checkpoint inhibitors. The application of the Naranjo scale provided a quantitative assessment of the likelihood that pembrolizumab induced adrenal insufficiency. Emergency department protocols should incorporate endocrine evaluations for patients presenting with non-specific symptoms while undergoing immunotherapy. Pembrolizumab can lead to severe endocrine disorders, such as Addison's disease, which can result in life-threatening conditions like severe hyponatremia. Emergency clinicians must remain vigilant in recognizing and treating these adverse effects to optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.